Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,481
  • Shares Outstanding, K 186,104
  • Annual Sales, $ 98,430 K
  • Annual Income, $ -118,960 K
  • EBIT $ -155 M
  • EBITDA $ -150 M
  • 60-Month Beta 0.62
  • Price/Sales 1.29
  • Price/Cash Flow N/A
  • Price/Book 9.21
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings $-0.22 on 05/08/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 211.77% ( -45.36%)
  • Historical Volatility 111.36%
  • IV Percentile 77%
  • IV Rank 33.22%
  • IV High 620.58% on 04/16/25
  • IV Low 8.38% on 06/17/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 900
  • Volume Avg (30-Day) 1,028
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 44,423
  • Open Int (30-Day) 49,833

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.19
  • Number of Estimates 7
  • High Estimate -0.16
  • Low Estimate -0.25
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +24.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5700 +21.93%
on 05/08/25
0.8248 -15.74%
on 04/30/25
+0.0586 (+9.21%)
since 04/17/25
3-Month
0.4300 +61.63%
on 04/09/25
0.9999 -30.49%
on 02/21/25
-0.3050 (-30.50%)
since 02/19/25
52-Week
0.4300 +61.63%
on 04/09/25
1.7700 -60.73%
on 05/20/24
-1.0600 (-60.40%)
since 05/17/24

Most Recent Stories

More News
Nektar: Q1 Earnings Snapshot

Nektar: Q1 Earnings Snapshot

NKTR : 0.6950 (+1.46%)
Nektar: Q4 Earnings Snapshot

Nektar: Q4 Earnings Snapshot

NKTR : 0.6950 (+1.46%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 74.82 (-0.35%)
DYN : 11.66 (-1.44%)
CRDL : 1.1200 (+0.90%)
AMRX : 7.50 (-1.32%)
NKTR : 0.6950 (+1.46%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 74.82 (-0.35%)
DYN : 11.66 (-1.44%)
CRDL : 1.1200 (+0.90%)
AMRX : 7.50 (-1.32%)
NKTR : 0.6950 (+1.46%)
Insider Sale: Chief R&D Officer of $NKTR (NKTR) Sells 7,785 Shares

Jonathan Zalevsky, the Chief R&D Officer of $NKTR ($NKTR), sold 7,785 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.1%...

NKTR : 0.6950 (+1.46%)
Nektar: Q3 Earnings Snapshot

Nektar: Q3 Earnings Snapshot

NKTR : 0.6950 (+1.46%)
Wall Street is Overlooking This Penny Stock, Says Analyst

This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.

AAPL : 208.78 (-1.17%)
AMZN : 206.16 (+0.28%)
NKTR : 0.6950 (+1.46%)
Nektar: Q2 Earnings Snapshot

Nektar: Q2 Earnings Snapshot

NKTR : 0.6950 (+1.46%)
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...

NKTR : 0.6950 (+1.46%)
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...

NKTR : 0.6950 (+1.46%)

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 0.7560
2nd Resistance Point 0.7258
1st Resistance Point 0.7104
Last Price 0.6950
1st Support Level 0.6648
2nd Support Level 0.6346
3rd Support Level 0.6192

See More

52-Week High 1.7700
Fibonacci 61.8% 1.2581
Fibonacci 50% 1.1000
Fibonacci 38.2% 0.9419
Last Price 0.6950
52-Week Low 0.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar